BiotechTube
Sensimed

Sensimed

Lausanne, Switzerland· Est.
sensimed.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

Sensimed is a pioneer in digital ophthalmology, commercializing the first and only CE-marked and FDA-approved contact lens sensor for continuous intraocular pressure monitoring. Its core product, the SENSIMED Triggerfish®, captures 24-hour ocular dimensional change profiles, providing clinicians with unprecedented data to manage glaucoma. The company is now focused on building a global registry to analyze this data, identify pathological patterns, and drive personalized treatment approaches. Since late 2019, Sensimed has been majority-owned by Japanese contact lens giant SEED Co., Ltd., which is leveraging the partnership for expansion in Asia.

OphthalmologyGlaucoma

Technology Platform

Smart contact lens with embedded micro-sensor (MEMS) for continuous, 24-hour monitoring of ocular dimensional changes (a proxy for intraocular pressure), coupled with a wearable data recorder and clinical analytics software.

Funding History

3
Total raised:$60M
Series C$30M
Series B$20M
Series A$10M

Opportunities

The global shift towards personalized medicine and remote patient monitoring creates a significant opportunity for Sensimed's continuous data solution.
Partnership with SEED provides direct access to the large and growing Asian glaucoma market.
Building a proprietary registry of longitudinal IOP and treatment data could create a valuable asset for insights, drug development partnerships, and shaping future standards of care.

Risk Factors

Commercial adoption is slowed by the need to change entrenched clinical practices and secure consistent insurance reimbursement.
The long-term clinical utility and cost-effectiveness of continuous IOP monitoring versus standard care still requires extensive real-world validation.
The company faces potential future competition from other non-invasive or implantable continuous monitoring technologies in development.

Competitive Landscape

Sensimed's SENSIMED Triggerfish® is first-in-class and currently has no direct commercial competitor offering continuous 24-hour IOP profiling via a contact lens. It competes indirectly with traditional spot-check tonometers and with emerging technologies in development, such as implantable micro-sensors (e.g., Eyemate by Implandata Ophthalmic Products) and other smart lens concepts. Its primary competition is the inertia of the current standard of care.

More companies in Switzerland →